Study guide
11.2 Antibody Detection & Crossmatch
Specialist in Blood Banking, SBB ASCP
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Overview
1.1 Current Exam Facts 1.2 Eligibility Routes & Credential Maintenance 1.3 Study Strategy for SBB
2 Donors & Collection
2.1 Donor Qualification 2.2 Collection Methods & Adverse Reactions 2.3 Special Donations
3 Processing, Storage & Component QC
3.1 Processing, Testing & Labeling 3.2 Storage, Transport & Expiration 3.3 Blood Component Quality Control
4 Red Cell & Modified Components
4.1 Whole Blood & Red Blood Cells 4.2 Leukocyte-Reduced, Washed, Frozen & Rejuvenated RBCs 4.3 Irradiated Components 4.4 Granulocytes
5 Platelets, Plasma & Cellular Products
5.1 Platelets 5.2 Plasma & Cryoprecipitated AHF 5.3 Apheresis Products & Fractionation Products 5.4 Hematopoietic Progenitors
6 Genetics, ABO & Rh
6.1 Blood Group Genetics & Molecular Inheritance 6.2 ABO & Lewis Systems 6.3 Rh System 6.4 MNS, P1PK/Globoside & Ii
7 Other Blood Groups & Role in Transfusion
7.1 Kell, Kidd, Duffy & Lutheran 7.2 Other Systems & High/Low-Prevalence Antigens 7.3 HLA, Platelet-Specific & Granulocyte Antigens 7.4 Immunogenicity & Antigen Prevalence
8 Immunology Foundations
8.1 Immune Response 8.2 Immunoglobulins 8.3 Antigen-Antibody Interactions 8.4 Complement
9 Physiology, Hemostasis & HDFN
9.1 Physiology of Blood 9.2 Hemostasis and Coagulation 9.3 HDFN Pathophysiology & Detection 9.4 HDFN Treatment & Prevention
10 Cytopenias & Transplantation
10.1 Immune & Nonimmune Anemia 10.2 Thrombocytopenia & Neutropenia 10.3 Solid Organ Transplantation Support 10.4 Hematopoietic Progenitor Cell Transplantation
11 Routine Serologic Testing
11.1 Blood Grouping Tests 11.2 Antibody Detection & Crossmatch 11.3 Antibody Identification & Clinical Significance 11.4 Direct Antiglobulin Testing & Reagents
12 Special Serologic Methods
12.1 Enzymes, Enhancement Media & Lectins 12.2 Adsorptions, Elutions & Titrations 12.3 Cell Separations, Neutralization & Thiol Reagents 12.4 Chloroquine Diphosphate & EDTA-Glycine Acid
13 Molecular Platforms & Serologic QA
13.1 Molecular Blood Group Techniques 13.2 ELISA, Immunofluorescence, Solid Phase & Column Agglutination 13.3 Serologic Quality Assurance
14 Indications, Component Therapy & PBM
14.1 Indications for Transfusion 14.2 Component Therapy 14.3 Blood Administration & Patient Blood Management
15 Adverse Effects of Transfusion
15.1 Immunologic Transfusion Reactions 15.2 Nonimmunologic Reactions 15.3 Transfusion-Transmitted Diseases
16 Apheresis & Extracorporeal Circulation
16.1 Therapeutic Apheresis 16.2 Extracorporeal Circulation
17 Quality, Safety, Math & Instrumentation
17.1 Quality Assessment & Troubleshooting 17.2 Laboratory Safety 17.3 Laboratory Mathematics 17.4 Instrumentation
18 Laboratory Administration (SBB Only)
18.1 Financial Management 18.2 Operations & Information Technology 18.3 Personnel, Education & Training 18.4 Quality Management, Risk & Tissue Management
11.2 Antibody Detection & Crossmatch
Key Takeaways Explain This Topic AI
Electronic crossmatch requires two ABO/Rh determinations, no antibody history, and a validated computer system that blocks ABO-incompatible unit selection.
Immediate-spin and electronic crossmatch only detect ABO incompatibility; a full AHG crossmatch is required for any patient with a positive antibody screen or antibody history.
A historical antibody such as anti-Jka requires antigen-negative units and full AHG crossmatch even when the current antibody screen is negative, due to anamnestic response risk.
MSBOS targets a crossmatch-to-transfusion ratio of about 2:1 or lower to avoid over-ordering blood for low-risk procedures.
PEG enhances weak IgG antibody detection more than LISS but increases the risk of nonspecific aggregation if the AHG phase is not read promptly.
Last updated: July 2026
11.2 Antibody Detection & Crossmatch
SBB Focus: Choosing the correct crossmatch method is a patient-safety decision, not a formality. ASCP expects specialists to defend when electronic, immediate-spin, or full AHG crossmatch is serologically and procedurally appropriate — and to catch the scenarios where a negative screen today does not mean a patient is antibody-free.
What the Antibody Screen Actually Tests
The antibody screen (indirect antiglobulin test, IAT) mixes patient plasma with two or three group O reagent screening cells , each selected to express clinically important antigens — D, C, c, E, e, K, k, Fya, Fyb, Jka, Jkb, S, s, M, N, P1, Lea, Leb — in known combinations. The screen is read at three phases: immediate spin (IgM, cold-reactive), 37°C incubation , and AHG (IgG, warm-reactive), typically potentiated with LISS or PEG enhancement media to shorten incubation and increase IgG antibody uptake. A positive reaction at any phase means an unexpected, non-ABO antibody may be present and must be identified before compatible units are selected.
Screen-Negative vs. Screen-Positive Pathways
Screen negative, no antibody history: eligible for an abbreviated crossmatch (immediate spin or electronic).
Screen positive, or any history of a clinically significant antibody: a full antibody identification workup is required, and every unit selected must undergo a full AHG crossmatch , regardless of what specificity is ultimately identified.
Crossmatch Methods
Method What It Detects Requirements
Electronic (computer) crossmatch ABO incompatibility only, via validated logic Two ABO/Rh determinations on file (at least one from a current sample), no current or historical clinically significant antibody, a validated computer system that blocks ABO-incompatible unit selection with no manual override
Immediate-spin crossmatch ABO incompatibility only, by direct serologic testing Negative antibody screen, no antibody history; patient serum/plasma mixed with a donor cell aliquot and centrifuged immediately, read for agglutination or hemolysis
Full AHG (indirect) crossmatch ABO incompatibility plus any clinically significant antibody reactive through the AHG phase Required whenever the antibody screen is positive or the patient has any history of a clinically significant antibody; incubated with LISS/PEG at 37°C, washed, AHG added, and check cells used to validate every negative result
Electronic and immediate-spin crossmatch only rule out ABO incompatibility — neither reliably detects a clinically significant alloantibody. A patient with a real but weak or evanescent antibody can pass an immediate-spin crossmatch and still receive an incompatible unit.
Type and Screen Policy and MSBOS
A type and screen performs ABO/Rh typing and an antibody screen without physically crossmatching or reserving units, and is appropriate for procedures with a low probability of transfusion. Facilities use a Maximum Surgical Blood Order Schedule (MSBOS) , built from historical transfusion data, to standardize how many units are routinely crossmatched for common procedures. The goal is a crossmatch-to-transfusion (C:T) ratio of about 2:1 or lower — ordering far more units than are actually transfused wastes reagent red cells, technologist time, and blood inventory.
The SBB-Level Trap: The Evanescent Antibody
The exam-favorite scenario: a patient has a documented history of anti-Jka from three years ago, but today's antibody screen is negative . Kidd antibodies are notorious for dropping below detectable titers between transfusion episodes — this does not mean the antibody is gone. Because re-exposure can trigger a fast anamnestic (secondary) response and a delayed hemolytic transfusion reaction , the historical record always overrides today's negative screen: this patient must receive Jka-negative units , crossmatched by full AHG, regardless of the current screen result. Electronic and immediate-spin crossmatch are never appropriate once any clinically significant antibody has ever been documented for that patient.
Enhancement Media Trade-offs
LISS shortens incubation time and increases antibody uptake with minimal risk of nonspecific reactions. PEG potentiates weak IgG antibodies even further than LISS but promotes nonspecific protein aggregation that can mimic true agglutination if the AHG phase is not read promptly after adding check cells — a common source of false-positive panels for technologists unfamiliar with PEG kinetics.
Specimen Requirements and the Three-Day Rule
AABB Standards require that a pretransfusion sample used for antibody screening or crossmatch be collected within 3 days of the scheduled transfusion whenever the patient has been pregnant or transfused within the preceding 3 months , or when that history is unknown. The rationale is purely kinetic: a newly forming alloantibody from a recent transfusion or pregnancy can take days to weeks to become detectable, so a sample drawn too early can look falsely antibody-negative even though sensitization has already occurred. An SBB reviewing a discrepant or delayed hemolytic transfusion reaction workup should always check specimen collection date against transfusion and pregnancy history before trusting a negative screen from several days earlier — an expired specimen window is one of the most common root causes identified in delayed serologic transfusion reaction investigations.
Emergency Release Considerations
When a patient's clinical status cannot tolerate the time needed for a full crossmatch, facilities may issue uncrossmatched group O red cells (Rh-negative for females of childbearing potential and children) under an emergency release protocol, with ABO/Rh typing and crossmatching completed retrospectively as soon as a sample is available. This is a deviation from routine crossmatch policy, not a replacement for it, and must be documented as an emergency release per facility policy and AABB Standards.